Compare ADMA Biologics Inc (ADMA) vs ASE Technology Holding Co Ltd (ASX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs ASE Technology Holding Co Ltd — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while ASE Technology Holding Co Ltd trades at $39.88 (market cap $89.31B). The key difference: ASE Technology Holding Co Ltd is far larger — about 41.9× ADMA Biologics Inc's market cap, and ASE Technology Holding Co Ltd pays a 1.05% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ASX | |
|---|---|---|
Market Cap | $2.13B | $89.31B |
Sector | Health | Technology |
52-Week High | $20.38 | $45.12 |
52-Week Low | $7.60 | $9.50 |
Enterprise Value | $2.20B | $93.75B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ASE Technology Holding (ASX) trades at $39.65, down 5.3% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong quarterly earnings beats, with Q1 2026 EPS of $0.20 beating expectations of $0.1703. Revenue grew to $645.39B in 2025, with net income of $40.02B, while valuation ratios like P/E of 67.98 and P/B of 8.67 suggest premium pricing. Recent news highlights AI-driven demand boosting its LEAP advanced packaging business, with 2026 revenue projected above $3.5B.
Outlook remains positive due to AI infrastructure growth and margin expansion, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is 80% buy, with institutional sentiment buoyed by earnings momentum, though the stock's recent decline may reflect profit-taking after a 77.1% three-month surge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →
